In 2024, Modern Retina covered news from around the globe on clinical trials, technology in retina, trending topics in ...

The conference will be held January 13-16, 2025 in San Francisco, CA. Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development ...

A single lot (Lot 10101) of Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, 25 count, is being voluntarily recalled by Alcon Laboratories due to the detection of fungal material in a ...

A Helsinki University Hospital study found diabetes, glycemic control, or insulin therapy did not significantly affect anatomical or functional outcomes after epiretinal membrane surgery. A recent ...

Finnish researchers, Hanna Heloterä, Anna-Mari Viita, and Juha Laine, reported the results of a study in which they gained a better perspective on registry data and the changing workload in ...

4DMT announced the publication of preclinical data demonstrating the potential of the Therapeutic Vector Evolution (TVE) platform, intravitreal R100 vector, and the R100-based genetic medicine 4D-150.

Did you miss any of our print issues this year? Don’t worry, they are still available online. In an increasingly digital world, where news moves swiftly and time is crunched, digital reading has ...

Curacle plans to finalize its development strategy, including phase 2b and 3 trials, through a Type C meeting with the US FDA in February of 2025. Curacle presented the results of its phase 2a ...

A research team from Great Britain identified factors, such as mental health issues, lack of diabetic eye screening awareness, and transport difficulties, that interfere with attendance at annual ...

Panelists discuss how anti-VEGF therapies have dramatically improved visual outcomes in patients with age-related macular degeneration and diabetic macular edema over the past decade. Key challenges ...

Panelists discuss how aflibercept’s molecular structure contributes to its clinical efficacy as a standard treatment for retinal vascular diseases.